Advisory Board
The EUROmediCAT Advisory Board consists of clinical experts and a patient representative in relation to the four main chronic diseases of study: epilepsy, diabetes, asthma and depression. Members of the Advisory Board have a special interest in one or more of the chronic diseases covered by EUROmediCAT and, in particular, treatment issues relating to pregnancy, and are independent of the research team.
The purpose of the Advisory Board is to:
- ensure that the specific research questions asked by EUROmediCAT, and consequent research results, are highly relevant to improving current clinical practice and patient experience. The Advisory Board will not be asked to advise directly on research methodology.
- advise on the most effective dissemination of the results of EUROmediCAT in order to inform decision making by clinicians and patients regarding medication options in pregnancy in Europe.
- advise on the responsible publication of interim results where new signals of associations between medications and congenital anomalies are detected.
Members of the EUROmediCAT Advisory Board are: